GlaxoSmithKline
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Burden of Disease Among Subjects With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 341
- Registration Number
- NCT03436511
- Locations
- πͺπΈ
GSK Investigational Site, Valencia, Spain
A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects
Completed
- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- Other: Safety data collection (following routine vaccination)
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3016
- Registration Number
- NCT03438006
- Locations
- π¨π³
GSK Investigational Site, Shanghai, China
A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age
Phase 2
Completed
- Conditions
- Meningitis, Meningococcal
- Interventions
- Biological: MenACWYBiological: MenACWY liquid
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1707
- Registration Number
- NCT03433482
- Locations
- πΉπ·
GSK Investigational Site, Izmir, Turkey
First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699
Phase 1
Terminated
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: GSK3358699Drug: PlaceboBiological: GM-CSFBiological: LPSOther: Cantharidin
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT03426995
- Locations
- π¬π§
GSK Investigational Site, Cambridge, United Kingdom
Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging
Phase 1
Terminated
- Conditions
- Amyloidosis
- Interventions
- Drug: GSK2315698 (CPHPC)Drug: GSK2398852 (unlabeled anti-SAP mAb)Drug: 89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb)
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2
- Registration Number
- NCT03417830
- Locations
- πΈπͺ
GSK Investigational Site, Uppsala, Sweden
To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Common Cold
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2019-06-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT03415243
- Locations
- πΊπΈ
GSK Investigational Site, Lexington, Kentucky, United States
Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions
Phase 1
Completed
- Conditions
- Infections, Bacterial
- Interventions
- Drug: Test formulation ADrug: Reference formulation B
- First Posted Date
- 2018-01-24
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT03408392
- Locations
- πΏπ¦
GSK Investigational Site, Bloemfontein, Free State, South Africa
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
Phase 3
Completed
- Conditions
- Anaemia
- Interventions
- First Posted Date
- 2018-01-24
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 614
- Registration Number
- NCT03409107
- Locations
- π¬π§
GSK Investigational Site, Swansea, United Kingdom
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)
Phase 3
Completed
- Conditions
- Anaemia
- Interventions
- Drug: Matching placebo tabletsDrug: Daprodustat tabletsDrug: Saline vials or bagsDrug: Epoetin alfa vials
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 407
- Registration Number
- NCT03400033
- Locations
- π¬π§
GSK Investigational Site, Swansea, United Kingdom
Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)
Completed
- Conditions
- Wiskott-Aldrich Syndrome
- Interventions
- Other: Caregiver interview guideOther: Patient Interview guideOther: Sociodemographic questionnaireOther: Pediatric quality of life (PedsQL) questionnaireOther: Clinical questionnaire
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 19
- Registration Number
- NCT03399461
- Locations
- πΊπΈ
GSK Investigational Site, Collegeville, Pennsylvania, United States
Β© Copyright 2025. All Rights Reserved by MedPath